Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer

Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not achieved similar activity as single agents in solid tumors. Preclinical studies have demonstrated the activity of the combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Jianling, Zhang, Yuping, Malmrose, Paige K., Losh, Haley A., Newtson, Andreea M., Devor, Eric J., Thiel, Kristina W., Leslie, Kimberly K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763941/
https://www.ncbi.nlm.nih.gov/pubmed/35039480
http://dx.doi.org/10.1038/s41419-022-04508-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763941/
https://www.ncbi.nlm.nih.gov/pubmed/35039480
http://dx.doi.org/10.1038/s41419-022-04508-2

Ejemplares similares